Hepatocellular Carcinoma Risk Steadily Persists over Time Despite Long-Term Antiviral Therapy for Hepatitis B:A Multicenter Study
- Authors
- Kim, Seung Up; Seo, Yeon Seok; Lee, Han Ah; Kim, Mi Na; Lee, Eun Ju; Shin, Hye Jung; Lee, Yu Rim; Lee', Hye Won; Park, Jun Yong; Kim, Do Young; Ahn, Sang Hoon; Han, Kwang-Hyub; Um, Soon Ho; Tak, Won Young; Kweon, Young Oh; Kim, Beom Kyung; Park, Soo Young
- Issue Date
- Apr-2020
- Publisher
- American Association for Cancer Research
- Citation
- Cancer Epidemiology Biomarkers and Prevention, v.29, no.4, pp 832 - 837
- Pages
- 6
- Indexed
- SCIE
SCOPUS
- Journal Title
- Cancer Epidemiology Biomarkers and Prevention
- Volume
- 29
- Number
- 4
- Start Page
- 832
- End Page
- 837
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/28180
- DOI
- 10.1158/1055-9965.EPI-19-0614
- ISSN
- 1055-9965
1538-7755
- Abstract
- Background: Long-term antiviral therapy (AVT) for chronic hepatitis B (CHB) reduces the risk of hepatocellular carcinoma (HCC). We assessed the temporal trends in the incidence of HCC over time during long-term AVT among Asian patients with CHB. Methods: Patients with CHB receiving entecavir/tenofovir (ETV/TDF) as a first-line antiviral were recruited from four academic hospitals in the Republic of Korea. We compared the incidence of HCC during and after the first 5 years of ETV/TDF treatment. Results: Among 3,156 patients, the median age was 49.6 years and males predominated (62.4%). During the follow-up, 9.0% developed HCC. The annual incidence of HCC per 100 person years during the first 5 years (n = 1,671) and after the first 5 years (n = 1,485) was statistically similar (1.93% vs. 2.27%, P = 0.347). When the study population was stratified according to HCC prediction model, that is, modified PAGE-B score, the annual incidence of HCC was 0.11% versus 0.39% in the low-risk group (<8 points), 1.26% versus 1.82% in the intermediate-risk group (9-12 points), and 4.63% versus 5.24% in the high-risk group (>= 13 points; all P > 0.05). A Poisson regression analysis indicated that the duration of AVT did not significantly affect the overall trend of the incidence of HCC (adjusted annual incidence rate ratio = 0.85; 95% confidence interval, 0.66-1.11; P = 0.232). Conclusions: Despite long-term AVT, the risk of HCC steadily persists over time among patients with CHB in the Republic of Korea, in whom HBV genotype C2 predominates. Impact: Careful HCC surveillance is still essential.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.